Mid Cap Pharma Picks

Discussion in 'Ask A Query About Your Stock Picks And Portfolio' started by Parin Gala, Mar 20, 2015.

  1. Parin Gala

    Parin Gala A long term investor

    Joined:
    Mar 19, 2015
    Messages:
    252
    Likes Received:
    157
    Hello friends

    I would like to ask which companies in the mid cap pharma space can deliver huge gains in the years to come. Are there any companies which can be bought after today's correction in the mid cap pharma space? I am asking picks for portfolio for the next 5-7 years

    Regards.
    Parin.
     
  2. Meenakshi Razdan

    Meenakshi Razdan Administrator Staff Member Moderator

    Joined:
    Mar 19, 2015
    Messages:
    427
    Likes Received:
    150
    Good question. I have the same thought in my mind. Over the weekend, I will prepare a short write up on a couple of mid-cap Pharma stocks that I have in my watch list.
     
  3. saagar.abhishek

    saagar.abhishek New Member

    Joined:
    Mar 19, 2015
    Messages:
    4
    Likes Received:
    0
    May be suven.but it is already up
     
  4. Parin Gala

    Parin Gala A long term investor

    Joined:
    Mar 19, 2015
    Messages:
    252
    Likes Received:
    157
    I have Suven LifeScience, Natco Pharma, Ajanta Pharma, SPARC and Strides Arcolab on my radar to pick for the next 5-7 years. Would want opinion and guidance of fellow members.
     
  5. adijsg

    adijsg Member

    Joined:
    Mar 19, 2015
    Messages:
    51
    Likes Received:
    8
    May be you can go for abbott india it is a very gud stock and gettingvits act together ipca is also gud and strides arcolab is gud because it rewards minority share holders with special divident
     
  6. Parin Gala

    Parin Gala A long term investor

    Joined:
    Mar 19, 2015
    Messages:
    252
    Likes Received:
    157
    Even Shilpa Medicare has corrected a lot from the top. Motilal Oswal has listed it as a potential 100 bagger. Does anyone have any idea on Shilpa for the long term?
     
  7. Meenakshi Razdan

    Meenakshi Razdan Administrator Staff Member Moderator

    Joined:
    Mar 19, 2015
    Messages:
    427
    Likes Received:
    150
    Shilpa is undoubtedly overvalued from a short-term perspective. Its P/E of 43x is exorbitant for a mid-cap stock. However, the FDA has recently inspected its facilities (link). Also, the company is engaged in the high margin oncology sector for which there is enormous demand in developed markets. So, if the FDA approval comes through, the future would be bright for the Company.
     
  8. jalaj.anand

    jalaj.anand New Member

    Joined:
    Mar 21, 2015
    Messages:
    8
    Likes Received:
    0
    What is your view on granual india .it is going to split in the face value of rs 1 from Monday. It is also listed in the wcs of
    Mr RAMDEV agg's 100 begger stocks.
     
  9. stockjeet18

    stockjeet18 Member

    Joined:
    Mar 21, 2015
    Messages:
    121
    Likes Received:
    26
    I bought suven from midcap and sun pharma from large cap pharma ... I will buy those on every dips..many growth triggers ahead for both companies..
     
  10. Meenakshi Razdan

    Meenakshi Razdan Administrator Staff Member Moderator

    Joined:
    Mar 19, 2015
    Messages:
    427
    Likes Received:
    150
    Very sensible strategy.
     
Loading...